Renin angiotensin system: A novel target for migraine prophylaxis

Indian Journal of Pharmacology

Volumn 44, Issue 2, 2012, Pages 157-160

  Nandha, Ruchika ^a   Singh, Harpal ^b  

^a PANJAB UNIVERSITY   (India)

^b FORTIS HOSPITAL   (India)

Author keywords

angiotensin II receptor antagonists; Angiotensin converting enzyme inhibitors; migraine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; TELMISARTAN; TRIPTAN DERIVATIVE;

CLINICAL TRIAL (TOPIC); COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FAINTNESS; HEADACHE; HUMAN; HYPOTENSION; MIGRAINE; PROPHYLAXIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84858957380     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.93840     Document Type: Review

References (26)

1. Tronvik E, Stovner LJ, Schrader H, Bovim G. Involvement of the renin-angiotensin system in migraine. J Hypertens 2006;24:139-43.
2. Snow V, Wall EM, Mottur-Pilson C. Pharmacological management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002;37:840-9.
3. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA 2003;289:65-9.
4. Headache classification committee of the IHS. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1-96.
5. Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician 2006;73:72-8.
6. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007;47 Suppl 1:S52-7.
7. Kumar R. Recent advances in migraine preventive treatment on the basis of pathophysiological considerations. Trendz 2007;5:15-20.
8. Rahimtoola H, Buurrna H, Tijssen CC, Leufkens HG, Egberts AC. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibitor therapy-A pilot study. Pharmacoepidemiol Drug Saf 2004;13:41-7.
9. Lipton RB. Conventional management and novel modalities for improved treatment of chronic migraine. Neurology 2009;72(Suppl 1):S1-2.
10. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia 1981;1:229-32.
11. Baldi E, Conti P, Conti R, Fanciullacci M, Michelacci S, Salmon S, et al. Hypernociceptive syndromes and pharmacological inhibition of endogenous opioid degradation. Int J Clin Pharmacol Res 1986;6:193-7.
12. Paterna S, Di Pasquale P, Martino S, Arrostuto A, Ingurgio NC, Parrinello G, et al. Captopril versus Placebo in the prevention of hemicranias without aura-A randomized double blind study. Clin Ter 1992;141:475-81.
13. 1blockade normalizes cerebrovascular auto regulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000;31:2478-86.
14. Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY, et al. Angiotensin receptors in the nervous system. Brain Res Bull 1998;47:17-28.
15. Baltatu O, Afeche SC, Jose dos Santos SH, Campos LA, Barbosa R, Michelini LC, et al. Locally synthesized angiotensin modulates pineal melatonin generation. J Neurochem 2002;80:328-34.
16. 2 in vascular smooth muscle cells. Circ Res 2000;86:1266-72.
17. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002;51:507-16.
18. Kara I, Ozkok E, Aydin M, Orhan N, Cetinkaya Y, Gencer M. Combined effects of ACE and MMP-3 polymorphisms on migraine development. Cephalgia 2007;27:235-43.
19. Paterna S, Di Pasquale P, D'Angelo A, Seidita G, Tuttolomondo A, Cardinale A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133-6.
20. Kowa H, Fusayasu E, Ijiri T, Ishizaki K, Yasui K, Nakaso K, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neuroscience 2005;2:129-31.
21. Etminan M, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing headache systematic overview and meta-analysis. Am J Med 2002;112:642-6.
22. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995;8:470-1.
23. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomized, placebo controlled, crossover study. BMJ 2001;322:19-22.
24. Owada K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens Res 2004;27:441-6.
25. Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis - An open label study. Eur J Neurol 2007;14:701-3.
26. Diener HC, Gendolla A, Fruersenger A, Evers S, Straube A, Schumacher H, et al. Telmisartan in migraine prophylaxis: A randomized, placebo-controlled trial. Cephalalgia 2009;29:921-7.